[
  {
    "ts": null,
    "headline": "SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria",
    "summary": "Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.",
    "url": "https://finnhub.io/api/news?id=942e708c811a7acc8b8e39b0c04e10af06e9bd627bf0eb6c439f21004aa87773",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764085500,
      "headline": "SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria",
      "id": 137606108,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.",
      "url": "https://finnhub.io/api/news?id=942e708c811a7acc8b8e39b0c04e10af06e9bd627bf0eb6c439f21004aa87773"
    }
  },
  {
    "ts": null,
    "headline": "Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)",
    "summary": "Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatment Dupixent, which inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation, is now approved for patients across seven chronic, inflammatory diseases in the EU TARRYTOWN, N.Y. and PARIS,",
    "url": "https://finnhub.io/api/news?id=5e0a103201901ea39aa8a7a15fddce0fb55375145b8f885867767b32cdf16553",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764050400,
      "headline": "Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)",
      "id": 137601676,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatment Dupixent, which inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation, is now approved for patients across seven chronic, inflammatory diseases in the EU TARRYTOWN, N.Y. and PARIS,",
      "url": "https://finnhub.io/api/news?id=5e0a103201901ea39aa8a7a15fddce0fb55375145b8f885867767b32cdf16553"
    }
  }
]